Aspen Pharmacare Holdings (Aspen Pharmacare Holdings) 3-Year EBITDA Growth Rate : 10.10% (As of Dec. 2023)

View and export this data going back to 2006. Start your Free Trial

What is Aspen Pharmacare Holdings 3-Year EBITDA Growth Rate?

Aspen Pharmacare Holdings's EBITDA per Share for the six months ended in Dec. 2023 was $0.47.

During the past 12 months, Aspen Pharmacare Holdings's average EBITDA Per Share Growth Rate was 1.70% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 10.10% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 5.30% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 2.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Aspen Pharmacare Holdings was 46.50% per year. The lowest was -14.30% per year. And the median was 19.50% per year.

Competitive Comparison of Aspen Pharmacare Holdings's 3-Year EBITDA Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Aspen Pharmacare Holdings's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aspen Pharmacare Holdings's 3-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aspen Pharmacare Holdings's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Aspen Pharmacare Holdings's 3-Year EBITDA Growth Rate falls into.

Aspen Pharmacare Holdings 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Aspen Pharmacare Holdings (OTCPK:APNHF) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Aspen Pharmacare Holdings 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Aspen Pharmacare Holdings's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Aspen Pharmacare Holdings (Aspen Pharmacare Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aspen Pharmacare Holdings Ltd (OTCPK:APNHF) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

APN:South Africa APNHY:USA

Address

Douglas Saunders Drive, Aspen Place, 9 Rydall Vale Park, La Lucia Ridge, Durban, NL, ZAF

Website

https://www.aspenpharma.com

Aspen Pharmacare Holdings Ltd is a specialty pharmaceutical company with a commercial footprint covering more than 50 countries and complex manufacturing capabilities in both API and finished dose form. The company focuses on a broad range of post-patent, branded medicines and domestic brands spanning many therapeutic areas. The company has four business segments such as Active Pharmaceutical Ingredients (API) - this segment includes the API Chemicals business and non-heparin biochemical API business, Heparin - this segment includes the full value chain contribution from all heparin containing products including API and Finished Dose. Form (FDF) sales Key products include the Fraxiparine and MonoEmbolex heparin containing FDF products and FDF Steriles segment.

Aspen Pharmacare Holdings (Aspen Pharmacare Holdings) Headlines

From GuruFocus

Value Idea Contest: Aspen Pharmacare

By Matthew Sipos Matthew Sipos • 03-17-2019

Aspiring for Aspen Pharmacare Holdings Ltd's Dividend: A Comprehensive Analysis

By GuruFocus Research • 09-21-2023